QP not present in Company: Prohibition of Supply
Recommendation
2/3 September 2026
Copenhagen, Denmark
When “Human Error” isn’t enough: Successful Failure Investigation
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
A new Non-Compliance Report (NCR, Report No: 2017090955) was published on the EudraGMDP site. On 21 September 2017, the Danish Medicines Agency performed an inspection at EuroPharma.DK ApS in Denmark. EuroPharma.DK ApS performs parallel import, repacking and distribution of pharmaceutical products.
During that inspection, it was considered that the secondary packing operations at the site do not comply with Good Manufacturing Practice. This was also based on the following observations:
- QP not present in company for supervision and competent interaction with staff and management
- QA department understaffed
- Inadequate follow-up and implementation of CAPAs
- Insufficient handling of deviations and complaints
- Inadequate GDP implementation
As a consequence, the respective manufacturing authorisation was suspended and medicinal products must not be re-packed by EuroPharma DK or any of their contract manufacturers and must not be released and distributed. What's interesting is the fact that the GMP certificate which was withdrawn was just issued after an inspection on 8 March 2017.
Source: EudraGMDP Database (Report # 2017090955)
Related GMP News
26.08.2026GMP and "Planned Deviations" - a Contradiction?
19.08.2026Why Root Cause Analysis is the Key to efficient CAPA
19.08.2026EMA updates Guideline on implementing the Shortage Prevention Plan
19.08.2026FDA: Simplified Registration for U.S. Sites and Greater Complexity for Non-U.S. Sites
12.08.2026When Training Fails: FDA Warning Letters Highlight GMP Training Deficiencies in 2026
29.07.2026EU-GMP for Veterinary Medicinal Products: What will change in Switzerland?